EyePoint Pharmaceuticals
Case Overview
| Status: | Status: Investigating |
| Company Name: | Company Name: EyePoint Pharmaceuticals |
| Ticker: | Ticker: EYPT |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
On August 14, 2026, EyePoint released topline results in its Phase 3 LUGANO wet AMD trial for DURAVYU, revealing that DURAVYU missed the prespecified primary endpoint—change in best-corrected visual acuity versus on-label aflibercept. Previously, on March 25, 2026, President and CEO Jay S. Duker had stated they were “highly confident in the results of these trials [including Phase 3 LUGANO] at this point for a lot of reasons.” On June 9, he reiterated that they “remain quite confident and quite optimistic in the results and we think we can make a difference for patients.” On this news, the Company’s stock price declined $9.88, or 67%, to close at $4.87 on August 17, 2026.